Novel osteoporosis targets
Author:
- 8 January 2013
- journal article
- review article
- Published by Springer Nature in Nature Reviews Endocrinology
- Vol. 9 (2) , 72-74
Abstract
Researchers are trying to develop more efficient and safer antifracture treatments. Besides the ongoing promising clinical trials involving antibodies to the Wnt antagonist sclerostin or inhibition of the osteoclast enzyme cathepsin K, the year 2012 has seen several novel osteoporosis targets identified by using different methodological approaches.Keywords
This publication has 10 references indexed in Scilit:
- Fracture Risk and Zoledronic Acid Therapy in Men with OsteoporosisNew England Journal of Medicine, 2012
- Antibiotics in early life alter the murine colonic microbiome and adiposityNature, 2012
- WNT16 Influences Bone Mineral Density, Cortical Bone Thickness, Bone Strength, and Osteoporotic Fracture RiskPLOS Genetics, 2012
- Double protection for weakened bonesNature, 2012
- Osteoprotection by semaphorin 3ANature, 2012
- Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fractureNature Genetics, 2012
- The gut microbiota regulates bone mass in miceJournal of Bone and Mineral Research, 2012
- Genetics of OsteoporosisEndocrine Reviews, 2010
- Evolution of Mammals and Their Gut MicrobesScience, 2008
- Risk of Wrist Fracture in Women Is Heritable and Is Influenced by Genes That Are Largely Independent of Those Influencing BMDJournal of Bone and Mineral Research, 2005